BioSeeker Group AB Research Reports

Title	Published	Price
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma By: BioSeeker Group AB This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of lung cancer and melanoma. This extensive 540+ \| more...	2/6/2008	$5,175.00
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology By: BioSeeker Group AB All cancers arise as a result of the acquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage upon the cells in which they have occurred. Protein \| more...	11/5/2007	$2,744.00
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma By: BioSeeker Group AB Executive Summary This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the lung cancer and melanoma field. This extensive \| more...	9/14/2007	$3,864.00
Triple Analysis: Decoding Big Pharma's R&D Strategy In Oncology and Special Focus on Breast and Prostate Cancer By: BioSeeker Group AB Executive Summary This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the breast- and prostate cancer field. This extensive \| more...	9/14/2007	$3,864.00
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas By: BioSeeker Group AB Executive Summary This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the leukemia and lymphoma field. This extensive 500+ \| more...	9/14/2007	$3,864.00
Decoding Big Pharmas R&D Strategy in Oncology By: BioSeeker Group AB Introduction This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners \| more...	9/14/2007	$2,744.00
Analytical Tool - Targeted Therapeutics: Melanoma By: BioSeeker Group AB Analytical Tool - Targeted Therapeutics: Melanoma" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in melanoma R&D and business development. It is at the same time a map \| more...	7/19/2007	$4,340.00
Melanoma - Targeted Therapeutics By: BioSeeker Group AB The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. In the current alternatives for the treatment of malignant \| more...	7/19/2007	$2,184.00
Antibody Drug Target Atlas in Oncology By: BioSeeker Group AB The elaborate advances towards the blueprinting of the altered molecular networks that lie behind cancer development have paved the way for targeted therapy in cancer. There are currently more than 400 antibody based drugs in \| more...	6/12/2007	$2,744.00
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas By: BioSeeker Group AB In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative drug candidates. \| more...	6/12/2007	$3,864.00
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer By: BioSeeker Group AB In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Breast- and Prostate cancer, which are all subjects to an extensive number of innovative drug \| more...	6/11/2007	$3,864.00
Analytical Tool - Current & Future Lung Cancer Therapeutics By: BioSeeker Group AB Analytical Tool - Current & Future Lung Cancer Therapeutics is a premium combo product of "Current and Future Therapies for Lung Cancer: A Therapeutic & Competitive Insight" and "Lung Cancer Drug Pipeline Update 2006". \| more...	5/10/2007	$4,340.00
Analytical Tool - Lymphoma Therapeutics & Competitive Insights By: BioSeeker Group AB Analytical Tool - Lymphoma Therapeutics & Competitive Insights" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development. It is at the same time \| more...	5/10/2007	$4,340.00
Analytical Tool - Competitive Outlook on Cancer Vaccines By: BioSeeker Group AB Analytical Tool - Competitive Outlook on Cancer Vaccines" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer vaccine R&D and business development. It is also a map \| more...	5/10/2007	$4,340.00
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology By: BioSeeker Group AB Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in anti-angiogenesis R&D and business development in \| more...	5/10/2007	$4,340.00
Analytical Tool - Prostate Cancer: A Therapeutic & Competitive Insight By: BioSeeker Group AB Analytical Tool - Prostate cancer Therapeutics & Competitive Insights" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer R&D and business development. It is at the \| more...	5/10/2007	$2,184.00
Analytical Tool - Breast Cancer Therapeutics & Competitive Insights By: BioSeeker Group AB Analytical Tool - Breast Cancer Therapeutics & Competitive Insights" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in breast cancer R&D and business development. It is at the \| more...	5/10/2007	$4,340.00
Analytical Tool - Leukemia Therapeutics & Competitive Insights By: BioSeeker Group AB Analytical Tool - Leukemia Therapeutics & Competitive Insights" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in leukemia R&D and business development. It is at the same time \| more...	5/10/2007	$4,340.00
Targeted Therapeutics in Non-Small Cell Lung Cancer By: BioSeeker Group AB Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There \| more...	4/26/2007	$2,184.00
European Biotech Industry Guide 2007, 5th Ed. By: BioSeeker Group AB Executive Summary This exciting intelligence CD-ROM on European biotech industry has become better, stronger and more intelligent in its 5th Edition. The 5th Edition of European Biotech Industry Guide has not only been updated \| more...	2/7/2007	$671.00
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology By: BioSeeker Group AB In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Apoptotic agents, Protein Kinase Inhibitors and Anti-Angiogenic agents, which are all subjects to an extensive number of innovative \| more...	12/19/2006	$2,898.00
Hematological Cancers - A Therapeutic & Competitive Insight By: BioSeeker Group AB Introduction Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and \| more...	10/16/2006	$2,898.00
Analytical Tool - Hematological Cancers By: BioSeeker Group AB "Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is at the same time a \| more...	10/16/2006	$6,435.00
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology By: BioSeeker Group AB "Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in anti-angiogenesis R&D and business development in \| more...	10/10/2006	$4,030.00
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology By: BioSeeker Group AB Introduction With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes \| more...	10/9/2006	$1,638.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 2